News

  1. Erleada (apalutamide) gets positive opinion from the EMA

    New medicine shows statistically significant improvements for prostate cancer patients.

    backlit man on mountain arms out

    Read more »
  2. Front-end Web Developer

    Seeking an creative and skilled Frontend Web Developer to join our international team.

    Frontend Web Developer

    Read more »
  3. We are seeking a talented Web Developer (Back-end)

    We are looking for an outstanding Web Developer to be responsible for the coding, innovative design and layout of our website. 

    web developers sitting at a desk

    Read more »
  4. Legal Counsel and Regulatory Expert

    Want to join a dynamic startup and make your work count? Join a dynamic, multicultural and mission-driven social impact startup with real potential.

    Legal Counsel and Regulatory Expert

    Read more »
  5. Truxima (rituximab) gains FDA approval as the first biosimilar for Non-Hodgkin's Lymphoma

    A new biosimilar, Truxima (rituximab), shows comparable results to the reference medicine, Rituxan (rituximab), and takes FDA one step further toward expanding patient access to medicines.

    approved stamp with stars

    Read more »
  6. What is TheSocialMedwork? An insider view

    Our team shares their take on what we do at TheSocialMedwork.

    what is tsm

    Read more »
  7. Vyndaqel (tafamidis) prolongs life of FAP patients

    Positive news for patients with early-stage FAP; results from a Portuguese study show that a liver transplant or Vyndaqel may extend survivability.

    grandfather pointing into sea

    Read more »
  8. A new gene therapy on the horizon for SMA

    Zolgensma (onasemnogene abeparvovec-xxxx) to receive priority review by FDA as a one-time treatment of type 1 spinal muscular atrophy (SMA).

    baby outside reaching toward viewer

    Read more »
  9. Orkambi approved in Australia, will others follow?

    Australia provides reimbursement for cystic fibrosis medicine.

    family blowing bubbles

    Read more »
  10. Alunbrig (brigatinib) approved in Europe for another type of lung cancer

    The European Commission has approved Alunbrig (brigatinib) for the treatment of a specific type of lung cancer.

    eu stars

    Read more »
Posts loader